Patent ID: 8153126

Claim:
A method for treating a subject having or at risk of having a fibrosis disease mediated by αvβ6, comprising administering to the subject a composition comprising a monoclonal antibody that is an αvβ6 blocking antibody, or an antigen binding fragment thereof and a pharmaceutically acceptable carrier; thereby alleviating, or postponing the onset of, the fibrosis disease wherein the monoclonal antibody or antigen binding fragment in said composition is selected from the group consisting of: (a) an antibody or an antigen binding fragment of an antibody that comprises the same heavy and light chain polypeptide sequences as an antibody produced by hybridoma 6.1A8 (ATCC accession number PTA-3647); (b) an antibody that comprises the same heavy and light chain polypeptide sequences as an antibody produced by hybridoma 6.3G9 (ATCC accession number PTA-3649); (c) an antibody or an antigen binding fragment of an antibody that comprises the same heavy and light chain polypeptide sequences as an antibody produced by hybridoma 6.8G6 (ATCC accession number PTA-3645); (d) an antibody or an antigen binding fragment of an antibody that comprises the same heavy and light chain polypeptide sequences as an antibody produced by hybridoma 6.2B1 (ATCC accession number PTA-3646); (e) an antibody or an antigen binding fragment of an antibody that comprises comprises the same heavy and light chain polypeptide sequences as an antibody produced by hybridoma 7.1G10 (ATCC accession number PTA-3898); (f) an antibody or an antigen binding fragment of an antibody that comprises the same heavy and light chain polypeptide sequences as an antibody produced by hybridoma 7.7G5 (ATCC accession number PTA-3899); and (g) an antibody or an antigen binding fragment of an antibody that comprises the same heavy and light chain polypeptide sequences as an antibody produced by hybridoma 7.1 C5 (ATCC accession number PTA-3900).